CrushSCI.com
99.0平均天数
92.5中位天数
30最短天数
248最长天数
2652025发文量

Paper Review Records

全部论文审稿周期

20 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

90 天

Olaparib maintenance versus placebo or standard of care in ovarian cancer: a biomarker-driven systematic review and meta-analysis of randomized trials

作者
Farida Namozova; Isadora Mamede; Carolina Alves Felippe; Ellen Rodrigues; Carlos Stecca展开收起
作者单位
1. Tashkent Medical Academy, Tashkent, Uzbekistan; 2. Federal University of São João del-Re, Divinópolis, Brazil; 3. University of Grande Rio “José de Souza Herdy” (UNIGRANRIO), Rio de Janeiro, Brazil; 4. Department of Obstetrics and Gynecology, São Paulo Municipal Health, São Paulo, Brazil; 5. Division of Medical Oncology, BC Cancer, Abbotsford, Canada展开收起
PDF源文件 DOI 网页
248 天

Current therapeutic interventions to target cancer stem cells for metastasis

作者
Priyancka Arora; Rakesh Bhatia; Sheetal Sharma; Anupam Sharma; Subhash C. Chauhan; Jagmohan Singh; Anil Kumar Sharma展开收起
作者单位
1. Department of Biotechnology, Amity School of Biological Sciences, Amity University Punjab, Sahibzada Ajit Singh Nagar, India; 2. Department of Experimental Medicine and Biotechnology, PGIMER Chandigarh, Chandigarh, India; 3. Department of Physics, Guru Kashi University, Talwandi Sabo, Bathinda, India; 4. Department of Microbiology and Immunology, School of Medicine, University of Texas Rio Grande Valley (UTRGV), Edinburg, USA展开收起
PDF源文件 DOI 网页
30 天

AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC

作者
Tadayoshi Hashimoto; Taro Shibuki; Takao Fujisawa; Shogen Boku; Mizuho Kikuchi; Atsuko Shimizu; Tomoe Murakami; Yasutoshi Sakamoto; Izumi Miki; Naoko Iida; Haruki Kurano; Riu Yamashita; Jun Masuda; Kensuke Matsuda; Junichiro Yuda; Shugo Yajima; Shin Kobayashi; Zedao Liu; Masataka Amisaki; Mitsuho Imai; Yoshiaki Nakamura; Hideaki Bando; Hyoju Kim; Heon Yung Gee; Hee Seung Lee; Hyun Woo Park; Takayuki Yoshino展开收起
作者单位
1. Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan; 2. Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; 3. Perioperative Treatment Development Promotion Office, National Cancer Center Hospital East, Kashiwa, Japan; 4. Department of Hepato-biliary pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; 5. Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; 6. Department of Clinical Oncology, Kansai Medical University Hospital, Hirakata, Japan; 7. Division of Translational Informatics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan; 8. Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; 9. Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan; 10. Department of Urology, National Cancer Center Hospital East, Kashiwa, Japan; 11. Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan; 12. Department of Oncology, University of Oxford, Oxford, UK; 13. Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 Four Project, Yonsei University, Seoul, Republic of Korea; 14. Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University college of medicine, Seoul, Republic of Korea; 15. Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; 16. Global Center of Research Excellence for Advanced Medicine (G-CORE), Keio University School of Medicine, Tokyo, Japan展开收起
PDF源文件 DOI 网页
93 天

Guideline-concordant treatment and clinical outcomes in older patients with endometrial cancer in Japan: a retrospective single-institution study

作者
Kanako Kasuya; Naoko Komura; Satoshi Nakagawa; Tsuyoshi Takiuchi; Eiji Kobayashi; Kae Hashimoto; Yutaka Ueda; Kenjiro Sawada; Michiko Kodama展开收起
作者单位
1. Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan; 2. Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Oita, Japan; 3. Department of Advanced Prevention and Health Sciences, Wakayama Medical University, Wakayama, Japan; 4. Department of Obstetrics and Gynecology, Ehime University Graduate School of Medicine, Ehime, Japan展开收起
PDF源文件 DOI 网页
156 天

Identification and functional validation of lipid droplet-associated prognostic biomarkers in breast cancer via integrative multi-omics and machine learning approaches

作者
Jia Yao; Zhen Liu; Jing Zhang; Xiongzhi Long; Chen Chao; Liqin Yuan展开收起
作者单位
1. Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, People’s Republic of China; 2. National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Department of Metabolism and Endocrinology, Ministry of Education, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China展开收起
PDF源文件 DOI 网页
74 天

Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT 3 receptor antagonists and dexamethasone

作者
Takeshi Aoyama; Hirotoshi Iihara; Masakazu Abe; Makoto Wada; Keiko Iino; Tatsuo Akechi; Chiyo K. Imamura; Ayako Okuyama; Keiko Ozawa; Yong-Il Kim; Hidenori Sasaki; Eriko Satomi; Masayuki Takeda; Ryuhei Tanaka; Takako Eguchi Nakajima; Naoki Nakamura; Junichi Nishimura; Mayumi Noda; Kazumi Hayashi; Takahiro Higashi; Narikazu Boku; Koji Matsumoto; Yoko Matsumoto; Kenji Okita; Nobuyuki Yamamoto; Kenjiro Aogi展开收起
作者单位
1. Department of Pharmacy, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; 2. Department of Pharmacy, Gifu University Hospital, Gifu, Japan; 3. Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan; 4. Department of Psycho-Oncology, Osaka International Cancer Institute, Osaka, Japan; 5. School of Nursing, National College of Nursing, Tokyo, Japan; 6. Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; 7. Advanced Cancer Translational Research Institute, Showa Medical University, Tokyo, Japan; 8. Graduate School of Nursing Science, St. Luke’s International University, Tokyo, Japan; 9. Division of Survivorship, Institute for Cancer Control, National Cancer Center, Tokyo, Japan; 10. Division of Medical Oncology, Yodogawa Christian Hospital, Osaka, Japan; 11. Division of Medical Oncology, Hematology and Infectious Disease, Fukuoka University Hospital, Fukuoka, Japan; 12. Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan; 13. Department of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Japan; 14. Department of Pediatric Hematology/Oncology, International Medical Center, Saitama Medical University, Hidaka, Japan; 15. Department of Early Clinical Development, Kyoto University Graduate School of Medicine, Kyoto, Japan; 16. Department of Radiation Oncology, St. Marianna University, Kawasaki, Japan; 17. Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan; 18. Non-profit Organization Sasaeau-kai “Alpha”, Chiba, Japan; 19. Department of Clinical Oncology and Hematology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan; 20. Department of Public Health and Health Policy, The University of Tokyo, Tokyo, Japan; 21. Department of Oncology and General Medicine, Institute of Medical Science, IMSUT Hospital, University of Tokyo, Minato-ku, Tokyo, Japan; 22. Division of Medical Oncology, Hyogo Cancer Center, Akashi, Japan; 23. Non-profit Organization Ehime Cancer Support “Orange-no-kai”, Matsuyama, Japan; 24. Department of Surgery, Otaru Ekisaikai Hospital, Otaru, Japan; 25. Internal Medicine III, Wakayama Medical University, Wakayama, Japan; 26. Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan展开收起
PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。